Daniel H. Allemand

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1

J. Cidlowski, J. Roa, P. Yankilevich, 2016, Oncogene.